Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) had its price target decreased by BMO Capital Markets from $42.00 to $40.00 in a research note published on Thursday. BMO Capital Markets currently has a market perform rating on the stock.

Several other research firms have also recently issued reports on PCRX. HC Wainwright set a $59.00 target price on shares of Pacira Pharmaceuticals and gave the stock a buy rating in a research note on Thursday. BidaskClub cut shares of Pacira Pharmaceuticals from a sell rating to a strong sell rating in a research note on Wednesday. Cowen and Company reiterated a hold rating on shares of Pacira Pharmaceuticals in a research note on Wednesday. Canaccord Genuity reiterated a buy rating and issued a $56.00 target price on shares of Pacira Pharmaceuticals in a research note on Monday, July 31st. Finally, Royal Bank Of Canada set a $58.00 target price on shares of Pacira Pharmaceuticals and gave the stock a buy rating in a research note on Sunday, July 30th. Four equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $54.50.

Shares of Pacira Pharmaceuticals (PCRX) traded down 1.521% during trading on Thursday, hitting $37.225. The stock had a trading volume of 934,172 shares. The company’s market capitalization is $1.49 billion. The firm has a 50-day moving average of $46.37 and a 200 day moving average of $45.57. Pacira Pharmaceuticals has a 1-year low of $29.95 and a 1-year high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.06. The business had revenue of $70.90 million for the quarter, compared to analysts’ expectations of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 earnings per share. Equities research analysts predict that Pacira Pharmaceuticals will post ($0.07) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/06/pacira-pharmaceuticals-inc-pcrx-price-target-cut-to-40-00-by-analysts-at-bmo-capital-markets.html.

In other news, CAO Kristen Marie Williams sold 1,877 shares of the stock in a transaction on Monday, June 5th. The shares were sold at an average price of $43.32, for a total value of $81,311.64. Following the transaction, the chief accounting officer now owns 13,773 shares of the company’s stock, valued at approximately $596,646.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, President James S. Scibetta sold 20,000 shares of the stock in a transaction on Monday, May 15th. The stock was sold at an average price of $51.20, for a total transaction of $1,024,000.00. Following the completion of the transaction, the president now directly owns 47,084 shares in the company, valued at approximately $2,410,700.80. The disclosure for this sale can be found here. Insiders sold a total of 50,564 shares of company stock worth $2,506,682 in the last three months. Insiders own 6.60% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Tygh Capital Management Inc. bought a new position in shares of Pacira Pharmaceuticals during the first quarter worth approximately $5,021,000. Capital Fund Management S.A. bought a new position in shares of Pacira Pharmaceuticals during the first quarter worth approximately $300,000. Massmutual Trust Co. FSB ADV bought a new position in shares of Pacira Pharmaceuticals during the first quarter worth approximately $256,000. Public Employees Retirement Association of Colorado raised its position in shares of Pacira Pharmaceuticals by 12.4% in the first quarter. Public Employees Retirement Association of Colorado now owns 251,088 shares of the company’s stock worth $11,450,000 after buying an additional 27,635 shares during the last quarter. Finally, Biondo Investment Advisors LLC raised its position in shares of Pacira Pharmaceuticals by 15.5% in the first quarter. Biondo Investment Advisors LLC now owns 164,622 shares of the company’s stock worth $5,553,000 after buying an additional 22,149 shares during the last quarter.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.